Hybrid screening strategy for colorectal cancer optimizes health benefits and cost savings

A strategy that combines two effective colorectal cancer screening methods, fecal immunological testing and colonoscopy may improve prevention and detection of colorectal cancer and reduce costs, according to a new study.

The study, which was published in Clinical Gastroenterology and Hepatology (2013; 11(9):1158-1166), used a simulation model to test a hybrid screening strategy consisting of annual or biennial fecal immunological testing at younger ages (50 to 65 years of age), combined with a single colonoscopy when the patient is 66 years of age. This approach led to substantial reductions in colorectal cancer incidence and mortality--comparable to those of the currently recommended strategies--and reductions in costs. Adherence to colonoscopy at age 66 years is critical to maintain the effectiveness of this hybrid screening program.

"Although colonoscopy is recognized as the most comprehensive colorectal examination, its role in screening is viewed very differently across health-care systems. Fecal immunochemical tests are emerging as the tests of choice in many population-based colorectal cancer screening programs," said study author Uri Ladabaum, MD, MS, of Stanford University School of Medicine in California. "This modeling study suggests that a hybrid screening approach of fecal immunological test at younger ages and then a well-timed single colonoscopy in the mid-sixties offers the potential to deliver health benefits that are similar to those of the current screening strategies with lower resources demand."

Colorectal cancer is the second leading cause of cancer deaths among men and women in the United States, and it is largely preventable through proper screening. Current guidelines for colorectal cancer screening identify colonoscopy and fecal immunological testing as two of several possible screening strategies, beginning at age 50 years for all average-risk people. The guidelines place an emphasis on screening tests that can detect premalignant lesions (eg, colonoscopy), as opposed to primarily early-stage cancer (eg, guaiac-based fecal occult blood tests).

The current U.S. Preventive Services Task Force guidelines call for regular screening of both men and women for colorectal cancer starting at age 50 years and continuing until age 75 years by regimens including: annual high-sensitivity fecal immunological test; flexible sigmoidoscopy every 5 years (possibly combined with a high-sensitivity fecal immunological test every 3 years); or screening colonoscopy at intervals of 10 years.

Researchers of this study conducted a simulation trial with virtual patients to compare several different screening strategies combining fecal immunological testing, flexible sigmoidoscopy, and colonoscopy against the currently recommended regimens. They used the Archimedes model, which simulates human physiology, diseases, interventions, and health-care systems on a large scale.

"Uptake of screening, and adherence over time, are key determinants of the effectiveness of screening," added Ladabaum. "Hybrid strategies might have the advantage of requiring adherence with yearly or biennial testing for a limited number of cycles, and then with a single well-timed colonoscopy. Whether adherence with such a program is better than with fecal immunological test[ing] over longer periods, or with several colonoscopies through the years, is a question worthy of further research."
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs